<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36736306</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4164</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Molecular cell</Title><ISOAbbreviation>Mol Cell</ISOAbbreviation></Journal><ArticleTitle>What repeat expansion disorders can teach us about the Central Dogma.</ArticleTitle><Pagination><StartPage>324</StartPage><EndPage>329</EndPage><MedlinePgn>324-329</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2022.12.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1097-2765(22)01174-1</ELocationID><Abstract><AbstractText>Pathogenic repeat sequences underlie several human disorders, including amyotrophic lateral sclerosis, Huntington's disease, and myotonic dystrophy. Here, we speak to several researchers about how repeat sequences have been implicated in affecting all aspects of the Central Dogma of molecular biology through their effects on DNA, RNA, and protein.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Eric T</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Freudenreich</LastName><ForeName>Catherine H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Gromak</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Ankur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell</MedlineTA><NlmUniqueID>9802571</NlmUniqueID><ISSNLinking>1097-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009223" MajorTopicYN="Y">Myotonic Dystrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests E.T.W. is a cofounder of and consultant to Kate Therapeutics. A.J. is a member of the scientific advisory board of Molecular Cell. P.K.T. served as a consultant to Denali Therapeutics and holds a shared patent with Ionis Pharmaceuticals. Y.N. discloses the patent PCT/JP2017/23,162 related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36736306</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2022.12.017</ArticleId><ArticleId IdType="pii">S1097-2765(22)01174-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>